Activation of Akt/PKB in breast cancer predicts a worse outcome among endocrine treated patients

British Journal of Cancer

Volumn 86, Issue 4, 2002, Pages 540-545

  Perez Tenorio G ^a   Stal O ^a   Arnesson, L G ^a   Malmstrom A ^a   Nordenskjold B ^a   Nordenskjold K ^a   Bang H ^a   Kallstrom A C ^a   Einarsson, E ^a   Norberg, B ^a   Skoog, P ^a   Henning, A ^a   Sundquist, M ^a   Tejler, G ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Akt; Breast cancers; Endocrine treatment; erbB 2; Heregulin 1; PKB

Indexed keywords

GOSERELIN; GROWTH FACTOR; NEU DIFFERENTIATION FACTOR; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; TAMOXIFEN;

ADULT; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CELL CYCLE; CELL CYCLE S PHASE; FEMALE; FLOW CYTOMETRY; HORMONAL THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; STROMA CELL;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; GOSERELIN; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEUREGULIN-1; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; S PHASE; SURVIVAL RATE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 18244391514     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600126     Document Type: Article

References (46)

1. Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells
2. Role of AKT1 in 17beta-estradiol- and insulin-like growth factor I (IGF-I)-dependent proliferation and prevention of apoptosis in MCF-7 breast carcinoma cells
3. The proteins encoded by c-akt and v-akt differ in post-translational modification, subcellular localization and oncogenic potential
4. Role of translocation in the activation and function of protein kinase B
5. Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: Implications for mammary tumors
6. Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers. Implication for tumor biology and clinical behavior
7. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas
8. Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F
9. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: A new model for anti-estrogen resistance
10. Fibroblast-mediated acceleration of human epithelial tumor growth in vivo
11. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA
12. Cellular and molecular pharmacology of antiestrogen action and resistance
13. Protein kinase B (c-Akt): A multifunctional mediator of phosphatidylinositol 3-kinase activation
14. Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells
15. Insulin-like growth factor (IGF)-I regulates IGF-binding protein-5 gene expression through the phosphatidy-linositol 3-kinase, protein kinase B/Akt, and p70 S6 kinase signaling pathway
16. bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group study
17. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression
18. Phosphatidylinositol 3-kinase mediates heregulin-induced growth inhibition in human epithelial cells
19. Prognostic value of bcl-2 expression in invasive breast cancer
20. Heregulin regulates the actin cytoskeleton and promotes invasive properties in breast cancer cell lines
21. Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression
22. Identification of heregulin, a specific activator of p185erbB2
23. ERBB-2 overexpression confers PI 3′ kinase-dependent invasion capacity on human mammary epithelial cells
24. GnRH receptor and apoptotic signaling
25. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB
26. Platelet-derived growth factor-dependent activation of phosphatidylinositol 3-kinase is regulated by receptor binding of SH2-domain-containing proteins which influence Ras activity
27. Heregulin regulation of Akt/protein kinase B in breast cancer cells
28. Basic guide to the mechanisms of antiestrogen action
29. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer
30. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel
31. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway
32. G1-S transition defects occur in most breast cancers and predict outcome
33. Akt/Protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation
34. Isolation of the neu/HER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells
35. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells
36. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification
37. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas
38. Involvement of the pleckstrin homology domain in the insulin-stimulated activation of protein kinase B
39. Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: Implications for tumor development and progression
40. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: Amplification of AKT1 in a primary human gastric adenocarcinoma
41. Relationships of DNA ploidy, S-phase fraction and hormone receptor status to tumor stage in breast cancers detected by population screening
42. Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry
43. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase
44. Clinicopathologic analysis of amphiregulin and heregulin immunostaining in breast neoplasia
45. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): Increased invasiveness may contribute to poor prognosis
46. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway